<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540150</url>
  </required_header>
  <id_info>
    <org_study_id>97/04/FFM</org_study_id>
    <nct_id>NCT00540150</nct_id>
  </id_info>
  <brief_title>Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy</brief_title>
  <official_title>Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergopharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in
      contrast to the standard specific immunotherapy.

      Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22
      patients for 6 weeks with the shortened scheme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the shortened specific immunotherapy.</measure>
    <time_frame>may 2004 - march 2005</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxid (eNO) and immunogenicity (IgE, specific IgE, specific IgG) in both groups.</measure>
    <time_frame>may 2004 - march 2005</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)</intervention_name>
    <description>We treat each patient with mite-allergen following the two different protocols.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent of patient and/or parents

          -  age &gt;6 and &lt;18 years

          -  bronchial asthma I° or II°

          -  allergy on house dust-mite

        Exclusion Criteria:

          -  age &lt;6 and &gt;18 years

          -  vital capacity &lt;80% or FEV1 &lt;70%

          -  pregnancy

          -  inhalative or systemic steroid use

          -  bronchial asthma III° or IV°

          -  heavy exacerbation during the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University, Department of Pulmonology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Goethe University, Department of Pulmonology</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hansen I, Hörmann K, Stuck BA, Schneider-Gêne S, Mösges R, Klimek L. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)]. Laryngorhinootologie. 2003 Aug;82(8):558-63. German.</citation>
    <PMID>12915987</PMID>
  </reference>
  <reference>
    <citation>Tabar AI, Echechipía S, García BE, Olaguibel JM, Lizaso MT, Gómez B, Aldunate MT, Martin S, Marcotegui F. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005 Jul;116(1):109-18.</citation>
    <PMID>15990782</PMID>
  </reference>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2007</study_first_posted>
  <last_update_submitted>October 4, 2007</last_update_submitted>
  <last_update_submitted_qc>October 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2007</last_update_posted>
  <keyword>Immunotherapy</keyword>
  <keyword>Mite</keyword>
  <keyword>Asthma</keyword>
  <keyword>bronchial provocation</keyword>
  <keyword>SIT</keyword>
  <keyword>specific immunotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

